Specific immunotherapy in atopic eczema

Allergy and Clinical Immunology International

Volumn 19, Issue 3, 2007, Pages 100-103

  Werfel, Thomas ^a   Kapp, Alexander ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN ANTIBODY COMPLEX; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CETIRIZINE; CORTICOSTEROID; HOUSE DUST ALLERGEN; LORATADINE; PLACEBO; UNCLASSIFIED DRUG;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ARTICLE; ATOPIC DERMATITIS; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FOOD ALLERGY; HUMAN; IMMUNOTHERAPY; INSOMNIA; PATCH TEST; PATIENT COMPLIANCE; PRURITUS; RESPIRATORY TRACT ALLERGY; SKIN SENSITIZATION; UNSPECIFIED SIDE EFFECT;

EID: 35349027330     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: 10.1027/0838-1925.19.3.100     Document Type: Article

References (37)

1. Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, et al. Diagnosis and treatment of atopic eczema in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma, and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118:152-169 and Allergy 2006; 61:969-987-
2. Werfel T, Kapp A. Environmental and other major provocation factors in atopic eczema AD. Allergy 1998; 53:731-739
3. Ring J, Darsow U, Behrendt H. Role of aeroallergens in atopic eczema: Proof of concept with the atopy patch test. J Am Acad Dermatol 2001; 45:49-52
4. Turjanmaa K, Darsow U, Niggemann B, Rancé F, Vanto T, Werfel T. EAACI/GA(2)LEN Position paper: Present status of the atopy patch test. Allergy 2006; 61:1377-1384
5. Kluken H, Wienker T, Bieber T. Atopic eczema/eczema syndrome - A genetically complex disease. New advances in discovering the genetic contribution. Allergy 2003; 58:5-12
6. Malling HJ. Immunotherapy for rhinitis. Curr Allergy Asthma Rep 2003; 3:204-209
7. Nelson HS. Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2003; 111:793-798
8. Darsow U, Forer I, Ring J. Spezifische Hyposensibilisierung bei atopischem Ekzem. Allergologie 2005; 2:53-61
9. Di Prisco de Fuenmayor MC, Champion RH. Specific hyposensitization in atopic eczema. Br J Dermatol 1979; 101:697-700
10. Zachariae H, Cramers M, Herlin T, Jensen J, Kragballe K, Ternowitz T, Thestrup- Pedersen K. Non-specific immunotherapy and specific hyposensitization in severe atopic eczema. Acta Derm Venereol Suppl (Stockh) 1985; 114:48-54
11. Zachariae H, Cramers M, Herlin T, Jensen J, Kragballe K, Ternowitz T, et al. Non-specific immunotherapy and specific hyposensitization in severe atopic eczema. Acta Derm Venereol Suppl (Stockh) 1985; 114:48-54
12. Seidenari S, Mosca M, Taglietti M, Manco S, Nume G. Specific hyposensitization in atopic eczema. Dermatologica 1986; 172:229
13. Leroy BP, Boden G, Lachapelle JM, Jacquemin MG, Saint-Remy JM. A novel therapy for atopic eczema with allergen-antibody complexes: A double-blind, placebo-controlled study. J Am Acad Dermatol 1993; 28:232-239
14. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G, et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic eczema. Allergol Immunopathol 1994; 22:18-22
15. Bussmann C, Bockenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic eczema? J Allergy Clin Immunol 2006; 118:1292-1298
16. Grewe M. Hyposensibilisierung beim atopischen Ekzem. Allergo J 2000; 9:351-353
17. Heijer A. Hyposensitzation with aeroallergens in atopic eczema. Allergo J 1993; 2:3-7
18. Mosca M, Albani-Rocchetti G, Vigini MA, Ubezio S, Nume G, Di Silverio A. La vaccinoterapia sulinguale nella dermatite atopica. Ital Dermatol Venerol 1993; 128:79-83
19. Mastrandrea F, Serio G, Minelli M. Specific sublingual immunotherapy in atopic eczema: results of a 6-year-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr) 2000; 28:54-62
20. Pacor ML, Biasi D, Maleknia T. The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic eczema. Recenti Prog Med 1994; 85:273-277
21. Trofimowicz A, Rzepecka E, Hofman J. Clinical effects of specific immunotherapy in children with atopic eczema. Rocz Akad Med Bialymst 1995; 40:414-422
22. Zwacka G, Glaser S, Rieger B. Therapeutische Erfahrungen mit Pangramin-SLIT im Vergleich zu einer subcutanen Immuntherapie und zur symptomatischen medikamentosen Behandlung bei Kindern mit Asthma bronchiale, Rhinokonjunktivitis und atopischer Eczema. Allergologie 1996; 19:580-592
23. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22:440-446
24. Kaufmann HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic eczema: a placebo controlled study. Ann Allergy 1974; 32: 321-330
25. Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic eczema. Allergy 1998; 53: 1202-1207
26. Petrova SI, Berzhets VM, Albanova VI, Bystriskaia TF, Petrova NS. Immunotherapy in the complex treatment of patients with atopic eczema with sensitization to house dust mites. Zh Mikrobiol Epidemiol Immunobiol 2006; 1:33-36
27. Ring J. Successful hyposensitization treatment in atopic eczema: Results of a trial in monozygotic twins. Br J Dermatol 1982; 107:597-602
28. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic eczema, part I: evaluation of clinical score. Wiad Lek 2005; 58:47-55
29. Silny W, Czarnecka-Operacz M. Spezifische Immuntherapie bei der Behandlung von Patienten mit atopischer Eczema. Allergologie 2006; 29:171-183
30. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; 2:912-915
31. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, Grewe M, et al. Usefulness of specific immunotherapy in patients with atopic eczema and allergic sensitization to house dust mites: a multi-center, randomized, dose-response study. Allergy 2006; 61:202-205
32. Michils A, Farber CM, Van Vooren JP, Yernault JC, Duchateau J. Sustained benefit of interferon-alpha therapy and oral hyposensitization in severe atopic eczema. Br J Dermatol 1994; 130:134-135
33. Chait I, Allkins V Remission of life-long atopic eczema after hyposensitisation to house dust mite. Practitioner 1985; 229:609-612
34. Hedges LV, Olkin I. 1985. Statistical methods for meta-analysis. Orlando (FL): Academic Press
35. Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic eczema. Immunol Today 1998; 19:359-361
36. Werfel T, Morita A, Grewe M, Renz H, Wahn U, Krutmann J, et al. Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic eczema. J Invest Dermatol 1996; 107:871-876
37. Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW, Passalacqua G. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007 120:164-170